ArticleMedical science monitor : international medical journal of experimental and clinical research2025
Association of C₂HEST Score and New-Onset Atrial Fibrillation in Patients with Non-ST-Segment Elevation Myocardial Infarction.
Article in Medical science monitor : international medical journal of experimental and clinical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND New-onset atrial fibrillation (NOAF) frequently emerges as a complication in patients with non-ST-segment elevation myocardial infarction (NSTEMI). The relationship between the C₂HEST score, a risk stratification tool for cardiovascular diseases, and NOAF in patients with NSTEMI remains unclear. The objective of this study was to investigate the relationship between the C₂HEST score and NOAF in patients with NSTEMI. MATERIAL AND METHODS Patients who received a diagnosis of NSTEMI from September 2022 to March 2025 were consecutively enrolled. All patients successfully underwent percutaneous coronary intervention within 24 h (thrombolysis in myocardial infarction grade 3), and received electrocardiogram monitoring for at least 36 h. The C₂HEST score was calculated based on coronary artery disease, chronic obstructive pulmonary disease, hypertension, age, heart failure, and hyperthyroidism. RESULTS A total of 665 patients were enrolled in this study. The average age was 63.31±13.09 years, and male patients accounted for 73.08%. During hospitalization, 63 patients (9.47%) developed NOAF. Multivariate logistic regression analysis indicated that C₂HEST score (OR=1.95, 95% CI: 1.63-2.33) was an independent risk predictor for NOAF. Restricted cubic spline analysis revealed a linear correlation between the C₂HEST score and NOAF (P for overall <0.001). Receiver operating characteristic curve showed that the area under the curve of the C₂HEST score was 0.775 (95% CI: 0.724-0.836); the cut-off value was 2.5. CONCLUSIONS Elevated C₂HEST score was found to be an independent risk factor for the development of NOAF in patients with NSTEMI. There was a linear dose-response relationship between C₂HEST score and NOAF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.